|
NL129025C
(cg-RX-API-DMAC7.html)
*
|
1965-04-29 |
|
|
|
|
US3542729A
(en)
*
|
1968-03-19 |
1970-11-24 |
Sankyo Co |
Stabilization of synthetic polymers
|
|
BE790675A
(fr)
*
|
1971-10-29 |
1973-04-27 |
Science Union & Cie |
Nouveaux derives de l'oxa-1 diaza-3,8 spiro (4,5) decane
|
|
US4244961A
(en)
*
|
1978-10-26 |
1981-01-13 |
Syntex (U.S.A.) Inc. |
1-Oxa-3,8-diazaspiro[4.5]decan-2-ones antihypertensive agents
|
|
US4255432A
(en)
*
|
1979-09-06 |
1981-03-10 |
Syntex (U.S.A.) Inc. |
8-[2-3-Indolyl)ethyl]-1-oxa-3-,8-diazaspiro[4.5]decan-2-ones, pharmaceutical compositions thereof and methods of use thereof
|
|
ES517622A0
(es)
*
|
1982-11-23 |
1983-12-16 |
Faes |
Procedimiento de preparacion de un nuevo espirodecano.
|
|
YU150489A
(sh)
*
|
1989-08-10 |
1992-12-21 |
W.L. Gore & Co. Gmbh. |
Uređaj za ispitivanje odevnih predmeta na nepromočivost
|
|
HU204054B
(en)
*
|
1989-08-10 |
1991-11-28 |
Richter Gedeon Vegyeszet |
Process for producing new 1-oxa-2-oxo-8-azaspiro(4,5)decane derivatives and pharmaceutical compositions comprising same
|
|
FR2666583B1
(fr)
*
|
1990-09-06 |
1994-09-09 |
Adir |
Nouveaux derives du spiro [4.5] decane, leur procede de preparation et leurs compositions pharmaceutiques les renfermant.
|
|
FR2734265B1
(fr)
*
|
1995-05-17 |
1997-06-13 |
Adir |
Nouveaux composes spiro heterocycliques, leur procede de preparation et les compositions pharmaceutiques les contenant
|
|
US6982251B2
(en)
*
|
2000-12-20 |
2006-01-03 |
Schering Corporation |
Substituted 2-azetidinones useful as hypocholesterolemic agents
|
|
KR20040025889A
(ko)
*
|
2001-01-26 |
2004-03-26 |
쉐링 코포레이션 |
혈관성 질환을 치료하기 위한 스테롤 흡수 억제제와심혈관성 제제의 조합물
|
|
IL156422A0
(en)
*
|
2001-01-26 |
2004-01-04 |
Schering Corp |
The use of substituted azetidinone compounds for the treatment of sitosterolemia
|
|
BR0206639A
(pt)
*
|
2001-01-26 |
2004-02-25 |
Schering Corp |
Combinações de inibidor(es) da absorção do esterol com modificador(es) do sangue para o tratamento de condições vasculares
|
|
SI1413331T1
(sl)
*
|
2001-01-26 |
2008-02-29 |
Schering Corp |
Kombinacije fenofibrata peroksisomskega proliferator aktivirajocega receptorja (PPAR) z ezetimib zaviralcem absorpcije sterola za vaskularne indikacije
|
|
WO2002058733A2
(en)
*
|
2001-01-26 |
2002-08-01 |
Schering Corporation |
Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications
|
|
US7071181B2
(en)
*
|
2001-01-26 |
2006-07-04 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
|
|
AU2002240050A1
(en)
*
|
2001-01-26 |
2002-08-06 |
Schering Corporation |
Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(s) and treatments for vascular indications
|
|
EP1392287B8
(en)
*
|
2001-05-25 |
2007-01-10 |
Schering Corporation |
Use of substituted azetidinone derivatives in the treatment of Alzheimer's disease
|
|
DE10130020A1
(de)
*
|
2001-06-25 |
2003-12-04 |
Gruenenthal Gmbh |
Substituierte 1-Oxa-2,8-diaza-spiro[4.5]dec-2-en-derivate
|
|
DE10146275A1
(de)
|
2001-09-18 |
2003-04-24 |
Gruenenthal Gmbh |
Kombination ausgewählter Opioide mit Muscarin-Antagonisten zur Therapie der Harninkontinenz
|
|
US20030119808A1
(en)
*
|
2001-09-21 |
2003-06-26 |
Schering Corporation |
Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
|
|
BR0212907A
(pt)
*
|
2001-09-21 |
2004-10-13 |
Schering Corp |
Métodos para tratamento ou prevenção de inflamação vascular usando inibidor(es) da absorção de esteróis
|
|
US7056906B2
(en)
*
|
2001-09-21 |
2006-06-06 |
Schering Corporation |
Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
|
|
JP2005504091A
(ja)
*
|
2001-09-21 |
2005-02-10 |
シェーリング コーポレイション |
ステロール吸収阻害剤としてアゼチジノンを用いる黄色腫の処置
|
|
US7053080B2
(en)
*
|
2001-09-21 |
2006-05-30 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
|
|
GEP20074134B
(en)
|
2002-08-19 |
2007-06-25 |
Pfizer Prod Inc |
Combination therapy for hyperproliferative diseases
|
|
EP1562582A1
(en)
*
|
2002-11-06 |
2005-08-17 |
Schering Corporation |
Cholesterol absorption inhibitors for the treatment of demyelination
|
|
JP2006519869A
(ja)
*
|
2003-03-07 |
2006-08-31 |
シェーリング コーポレイション |
置換アゼチジノン化合物、置換アゼチジノン化合物を調製するためのプロセス、それらの処方物および使用
|
|
WO2004081002A1
(en)
|
2003-03-07 |
2004-09-23 |
Schering Corporation |
Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
|
|
US7459442B2
(en)
|
2003-03-07 |
2008-12-02 |
Schering Corporation |
Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
|
|
CN1756756A
(zh)
|
2003-03-07 |
2006-04-05 |
先灵公司 |
取代的2－吖丁啶酮化合物、其制剂及其治疗高胆甾醇血症的用途
|
|
US20050037063A1
(en)
*
|
2003-07-21 |
2005-02-17 |
Bolton Anthony E. |
Combined therapies
|
|
WO2005046797A2
(en)
*
|
2003-11-05 |
2005-05-26 |
Schering Corporation |
Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
|
|
EP1716156A2
(en)
*
|
2004-02-10 |
2006-11-02 |
F.Hoffmann-La Roche Ag |
Chemokine ccr5 receptor modulators
|
|
US20060063803A1
(en)
*
|
2004-09-23 |
2006-03-23 |
Pfizer Inc |
4-Amino substituted-2-substituted-1,2,3,4-tetrahydroquinoline compounds
|
|
GT200600381A
(es)
|
2005-08-25 |
2007-03-28 |
|
Compuestos organicos
|
|
US7741317B2
(en)
|
2005-10-21 |
2010-06-22 |
Bristol-Myers Squibb Company |
LXR modulators
|
|
US7888376B2
(en)
|
2005-11-23 |
2011-02-15 |
Bristol-Myers Squibb Company |
Heterocyclic CETP inhibitors
|
|
US7919506B2
(en)
|
2006-03-10 |
2011-04-05 |
Pfizer Inc. |
Dibenzyl amine compounds and derivatives
|
|
US8383660B2
(en)
|
2006-03-10 |
2013-02-26 |
Pfizer Inc. |
Dibenzyl amine compounds and derivatives
|
|
ATE547394T1
(de)
|
2006-12-01 |
2012-03-15 |
Bristol Myers Squibb Co |
N-((3-benzyl)-2,2-(bis-phenyl)-propan-1- aminderivate als cetp-hemmer für die behandlung von atherosklerose und herz-kreislauf- erkrankungen
|
|
CA2682639A1
(en)
*
|
2007-03-29 |
2008-10-09 |
F. Hoffmann-La Roche Ag |
Heterocyclic antiviral compounds
|
|
US8034782B2
(en)
|
2008-07-16 |
2011-10-11 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
|
US8969514B2
(en)
|
2007-06-04 |
2015-03-03 |
Synergy Pharmaceuticals, Inc. |
Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
|
|
ES2559319T3
(es)
|
2007-06-04 |
2016-02-11 |
Synergy Pharmaceuticals Inc. |
Agonistas de guanilato cliclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos
|
|
EP2328910B1
(en)
|
2008-06-04 |
2014-08-06 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
|
|
US9616097B2
(en)
|
2010-09-15 |
2017-04-11 |
Synergy Pharmaceuticals, Inc. |
Formulations of guanylate cyclase C agonists and methods of use
|
|
CN102766147B
(zh)
*
|
2012-08-03 |
2015-07-15 |
无锡药兴医药科技有限公司 |
一种芬司匹利及其氢卤酸盐的制备方法
|
|
WO2014151200A2
(en)
|
2013-03-15 |
2014-09-25 |
Synergy Pharmaceuticals Inc. |
Compositions useful for the treatment of gastrointestinal disorders
|
|
AU2014235215A1
(en)
|
2013-03-15 |
2015-10-01 |
Synergy Pharmaceuticals Inc. |
Agonists of guanylate cyclase and their uses
|
|
AU2014255381A1
(en)
|
2013-04-17 |
2015-10-08 |
Pfizer Inc. |
N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
|
|
BR112015030326A2
(pt)
|
2013-06-05 |
2017-08-29 |
Synergy Pharmaceuticals Inc |
Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos
|
|
GB201416346D0
(en)
*
|
2014-09-16 |
2014-10-29 |
Shire Internat Gmbh |
Spirocyclic derivatives
|
|
WO2016055901A1
(en)
|
2014-10-08 |
2016-04-14 |
Pfizer Inc. |
Substituted amide compounds
|
|
DK3911648T3
(da)
|
2019-01-18 |
2025-01-13 |
Astrazeneca Ab |
6'-[[(1s,3s)-3-[[5-(difluormethoxy)-2-pyrimidinyl]amino]cyclopentyl]amino][1(2h),3'-bipyridin]-2-on som pcsk9-hæmmer og fremgangsmåder til anvendelse deraf
|